Introduction
============

The emergence of bacterial resistance to conventional antibiotics is becoming a serious sanitary and economical threat. There is an urgent need to develop alternative drugs that address this global health issue and overcome the spread of infectious diseases ([@B37]; [@B44]). In particular, novel therapeutic approaches will be required to fight the dissemination of multi-drug resistant bacterial strains that threaten our public health system to return to the "pre-antibiotic era" ([@B81]). Currently, the majority of antimicrobial agents that are available in the pharmaceutical market rely on the direct elimination of the microorganisms. Notwithstanding, recent literature highlights the potentiality of drug combination and simultaneous targeting of diverse cellular processes ([@B12]; [@B35]) to overcome the bacterial development of resistance mechanisms. Being aware that full eradication of antibiotic resistance might be unattainable, we should gather all our available means to minimize its dissemination and impact. One of the favorite strategies to overcome the so called "antibiotic resistance era" relies on the discovery of unconventional drugs and combinatorial approaches ([@B14]).

In the search of novel antibiotic candidates, our own innate immunity system represents one of the best reservoirs. Upon infection, our innate immune cells secrete a variety of antimicrobial proteins and peptides (AMPs) that protect the host biological fluids against pathogen invasion. AMPs are usually small polypeptides that present a non-specific wide-spectrum targeting of microorganisms ([@B26]). A growing clinical interest for AMPs is derived from their low toxicity to mammalian cells, together with the fact that bacterial resistance to these molecules seems inherently more difficult to acquire in comparison to conventional antibiotics ([@B34]; [@B45]; [@B16]). Within the AMPs, the largest group corresponds to cationic peptides ([@B26]). The mode of action of cationic antimicrobial peptides is different from that of conventional antibiotics and is often related to interaction with bacterial walls through electrostatic forces and subsequent cell lysis ([@B83]; [@B2]). AMPs are mostly amphiphilic in nature and they are comprised of hydrophobic and hydrophilic residues aligned on opposite sides of the peptides, facilitating their easy penetration through cell membranes ([@B69],[@B70]; [@B10]). Fortunately, although several cases of bacterial resistance to AMPs have been observed ([@B50]; [@B43]), the complex structure of bacterial envelopes hinder the development of total resistance. Besides, AMPs are frequently multifaceted molecules that combine a direct mechanical action to the bacterial envelope with a specific enzymatic activity that targets essential intracellular macromolecule components. A variety of multifunctional antimicrobial proteins, endowed with protease, DNase or RNase activity, can participate in the host defense system ([@B13]; [@B28]; [@B7]; [@B1]).

In our laboratory, we are working on the structure-functional relationship of human antimicrobial RNases that belong to the vertebrate-specific RNase A superfamily and are secreted by epithelial and blood cells during infection ([@B25]; [@B31]; [@B39]). Characterization of the mechanism of action of human antimicrobial RNases suggests that a combination of activities are taking place ([@B61]; [@B39]). In particular, the human RNase 3, mostly secreted by eosinophils upon infection, combines a high cationicity (pI ∼11), lipopolysaccharide (LPS) binding affinity, membrane destabilization and bacterial agglutination activities ([@B8]; [@B76]).

Interestingly, a striking structural homology between the RNase A superfamily and bacterial RNases belonging to the contact-dependent growth inhibition (CDI) toxins was recently reported ([@B3]; [@B17]). CDI bacterial toxins work as inter-strain competition weapons and use the RNase enzymatic activity as a self-defense mechanism. Indeed, most of our current antibiotics are derived from natural compounds produced by microorganisms against competing species ([@B4]). Among them, bacteriocins, expressed by commensal species and endowed with enzymatic activities, are being considered as appealing alternative antibiotics to fight pathogenic strains ([@B40]).

Another alternative approach proposed to fight resistance mechanisms against antimicrobial agents is the targeting of the bacterial community integrity. Recent studies reveal the previously underestimated complexity of bacterial communities and identify collective resistance mechanisms ([@B78]). Novel strategies can be engineered to target the bacterial community cohesion and thereby weaken collective resistance. Collective resistance ensures the survival of the microbial community upon exposure to antibiotic conditions that otherwise would be lethal to individual bacterial cells ([@B78]). One of the main mechanisms that ensures bacterial survival relies on the intercellular horizontal transfer of information that facilitates a rapid response to any external injury and ensures the community's adaptation to a hostile environment ([@B48]). Recent discoveries have identified signaling molecules that contribute to community quorum sensing, such as regulatory small RNAs ([@B49]). Therefore, an antimicrobial agent endowed with RNase activity that can target bacterial quorum-sensing signaling might work as an antibiotic adjuvant. Indeed, the use of antibiotic adjuvants is one of the selected strategies to minimize the emergence and impact of resistance phenomena ([@B81]). Addition of adjuvants can lower the needed antibiotic dose to reach a therapeutic effect ([@B14]). Moreover, weakening the bacterial community cohesion would reduce the emergence and dissemination of resistant pathogenic strains ([@B66]).

In this study, we have committed ourselves to evaluating the potential contribution of RNase catalytic activity in reducing the emergence of bacterial resistance. Toward this end, we have used an experimental evolution assay by exposing an *Acinetobacter baumannii* bacterial culture to increasing concentrations of colistin. Colistin (also called polymyxin E) is a non-ribosomal bacterial cyclic AMP only used in the clinics as a last resort to treat live-threatening infections, due to its reported toxicity. Here, we have tested the reduction of the antimicrobial resistance against colistin upon treatment with an engineered RNase construct that combines a high catalytic activity with specific antimicrobial properties.

Materials and Methods {#s1}
=====================

Materials
---------

The *A. baumannii* strain (CECT 452; ATCC 19606) and *Pseudomonas aeruginosa* strains (CECT 4122; ATCC 15692) are from the Spanish Type Culture Collection (CECT). The *Escherichia coli* BL21(DE3) strain and the pET11c plasmid are from Novagen. MRC-5 and HepG2 cells are from the American Type Cell Culture Collection (ATCCC). Mueller--Hinton broth, LPS and RNase A (Type XII) are from Sigma-Aldrich. 3-\[4,5-dimethylthiazol-2-yl\]-2,5-diphenyl tetrazolium bromide (MTT), Isopropyl β-D-1-thiogalactopyranoside (IPTG) and colistin are from Apollo Scientific. 1-aminonaphthalene-3,6,8-trisulfonate (ANTS), α,α′-dipyridinium p-xylene dibromide (DPX) and the fluorescent probe BODIPY TR cadaverine are from Molecular Probes. Toludine blue is from Merck. RNase 3/1 gene was purchased from NZYTech. 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-*sn*-glycero-3-phosphoglycerol (DOPG) were from Avanti Polar Lipids. *E. coli* lipid extract was obtained as described ([@B21]). Human RNase 1 gene was a gift from Dr. Maria Vilanova, Universitat de Girona, Spain, and human RNase 3 sequence was taken from a previously synthesized gene ([@B6]).

Protein Expression and Purification
-----------------------------------

The RNase 1, 3, and 3/1 genes were subcloned into the plasmid pET11c for prokaryote high yield expression in the *E. coli* BL21(DE3) strain. The recombinant protein was expressed and purified as previously described ([@B5]), with some modifications ([@B47]). Briefly, bacteria were grown in terrific broth (TB), containing 400 μg/mL ampicillin. Recombinant protein was expressed after cell induction with 1 mM IPTG added when the culture showed an OD~600~ of 0.6. The cell pellet was collected after 4 h of culture at 37°C. Cells were resuspended in 10 mM Tris/HCl and 2 mM EDTA, pH 8 and 40 μg/mL of lysozyme, and sonicated after 30 min. The pellet was suspended in 25 mL of the same buffer with 1% triton X-100 and 1 M urea and was left stirring at room temperature for 30 min, before being centrifuged for 30 min at 22.000 × *g*. This procedure was repeated until the supernatant was completely transparent. In order to remove the triton X-100, 200 mL of 10 mM Tris-HCl pH 8.5, 2 mM EDTA was added to the pellet and centrifuged again for 30 min at 22.000 × *g*. The resulting pellet was suspended in 25 mL of Tris-acetate 100 mM, pH 8.5, 2 mM EDTA, 6 M guanidine hydrochloride, and 80 mM of DTT. The protein was then refolded for 72 h at 4°C by a rapid 100-fold dilution into 100 mM Tris/HCl, pH 8.5, 0.5 M of guanidinium chloride, and 0.5 M L-arginine, and oxidized glutathione (GSSG) was added to obtain a DTT/GSSG ratio of 4. The folded protein was then concentrated, buffer-exchanged against 150 mM sodium acetate, pH 5 and purified by cation-exchange chromatography on a Resource S (GE Healthcare) column equilibrated with the same buffer. The protein was eluted with a linear NaCl gradient from 0 to 2 M in 150 mM sodium acetate, pH 5. The protein purity was checked by SDS-PAGE and reverse-phase HPLC. Absence of unpaired Cys was confirmed by the Ellman's reaction ([@B20]).

Circular Dichroism (CD)
-----------------------

Far-UV CD spectra were obtained from a Jasco-715 (Jasco), as previously described ([@B72]). The spectra were registered from 195 to 240 nm at room temperature. Data from four consecutive scans were averaged. Before reading, the sample was centrifuged at 10.000 × *g* for 5 min. Protein spectra were obtained at 6 μM in 5 mM sodium phosphate, pH 7.5, with a 0.2 cm path-length quartz cuvette. The percentage of secondary structure was estimated with Spectra Manager II, as described ([@B82]).

Activity Staining Gel
---------------------

Zymograms were performed following the method previously described ([@B11]). 15% polyacrylamide-SDS gels were cast with 0.3 mg/mL of poly(C) (Sigma Aldrich). Then, 20 ng of RNase 1, 3, and 3/1 were loaded, and the gel was run at a constant current of 100 V for 1.5 h. Following, the SDS was removed from the gel with 10 mM Tris/HCl, pH 8, and 10% (v/v) isopropanol. The gel was then incubated during 1 h in the activity buffer (100 mM Tris/HCl, pH 8) to allow enzymatic digestion of the embedded substrate and then stained with 0.2% (w/v) toluidine blue in 10 mM Tris/HCl, pH 8, for 10 min. Positive bands appeared white against the blue background. The loading buffer had no 2-mercaptoethanol to facilitate recovery of active enzymes.

Minimum Bactericidal Concentration (MBC) Determination
------------------------------------------------------

MBC~100~ was defined as the lowest protein/peptide concentration that completely eradicated bacterial cells. RNase 3/1 was serially diluted in HBS (HEPES 20 mm pH 7.4, NaCl 100 mM) in 96-well plate in a volume of 100 μL to achieve final concentrations from 20 to 0.02 μM. Then, 2 μL of an exponential phase subculture of *E. coli, A. baumannii* or *P. aeruginosa* was added, previously adjusted to give a final concentration of approximately 5 × 10^5^ colony-forming units (CFU)/mL in each well and the plate was incubated for 4 h at 37°C and 100 rpm. Finally, samples were plated onto LB (Condalab) Petri dishes and incubated at 37°C overnight. All the assays were performed in triplicate.

Cytotoxicity Assay
------------------

Cytotoxicity was measured for the MRC-5 and HepG2 human cell lines using the MTT assay, as described previously ([@B55]). Cells were grown in 5% CO~2~ at 37 °C with minimal essential medium supplemented with 10% fetal bovine serum (FBS). Cells were plated at 5 × 10^4^ cells/well in a 96-well plate and incubated overnight. Next, the medium was removed and serial dilutions of RNase 1, 3, and 3/1 were added at concentrations ranging from 200 to 0.2 μM in 100 μL of medium without serum. After 4 h of incubation, the medium was replaced with fresh medium containing 0.5 mg/mL MTT solution and the mixture was incubated for 2 h in 5% CO~2~ at 37 °C. The medium was then removed and formazan was dissolved by adding acidic isopropanol. The optical density (OD) was recorded by using a Victor^3^ plate reader (PerkinElmer, Waltham, MA) set at 550 and 630 nm as references. Reference absorbance at 630 nm was used to correct for nonspecific background values. Each experiment was repeated at least three times.

LPS Binding Assay
-----------------

The LPS-binding affinity was assessed using the fluorescent probe BODIPY TR cadaverine (BC) as described ([@B74]). RNase 1, 3, and 3/1were serially diluted in a 96-well fluorescence plate from 20 to 0.02 μM in HEPES 10 mm pH 7.4. Then, LPS (10 μg/mL) and BC (10 μM) were added in the same buffer. Fluorescence measurements were performed on a Victor^3^ plate reader. The BC excitation wavelength was 580 nm, and the emission wavelength was 620 nm. Occupancy factor was calculated as described previously ([@B74]).

Liposome Preparation
--------------------

Large unilamellar vesicles (LUVs) containing DOPC/DOPG (3:2 molar ratio, 1 mM stock concentration) or *E. coli* membrane lipids (5 mg/mL stock concentration) of a defined size were obtained from a vacuum drying lipid chloroform solution. After the chloroform evaporation, liposomes were suspended with 10 mM Tris/HCl, 20 mM NaCl, pH 7.4. The distribution and the mean hydrodynamic range of the liposomes in suspension was determined by dynamic light scattering (DLS) with a Zetasizer Nano ZS Malvern, and the data was analyzed by its built-in software (Zetasizer 7.02).

Liposome Leakage
----------------

The ANTS/DPX liposome leakage fluorescence assay was performed as previously described ([@B51]). Briefly, a unique population of LUVs DOPC/DOPG (3:2) or *E. coli* liposomes was prepared to encapsulate a solution containing 12.5 mM ANTS, 45 mM DPX, 20 mM NaCl, and 10 mM Tris/HCl, pH 7.5 by applying three freeze-thaw cycles. The ANTS/DPX liposome stock suspension was diluted to 30 μM and incubated at 37°C for 1 h with RNase 1, 3, and 3/1, serially diluted from 20 to 0.015 μM in a microtiter fluorescence plate. Fluorescence measurements were performed on a Victor^3^ plate reader with an excitation wavelength of 386 nm and an emission wavelength of 535 nm. ED~50~ values were calculated by fitting the data to a dose--response curve with Origin 8.0.

Synergy Determination Assay
---------------------------

The synergy test was carried out by determining the bacterial minimum inhibitory concentration (MIC) in Müller Hinton medium, as follows. 8 × 8 well plates were used to check the protein/colistin combinations. First, RNase 3/1 was serially diluted from 12 to 0.1 μM, in eppendorf tubes at a 10-fold the final concentration in 0.01% acetic acid ([@B80]). Then, colistin was serially diluted from 8 to 0.02 μM in Mueller--Hinton medium to a final volume of 90 μL, and 10 μL of the serially diluted protein aliquots were added in each corresponding well (except in the negative control, where only buffer was added). After that, 2 μL of a 1:3 diluted 24-h culture of *A. baumannii* were added to each well to achieve a final 1:150 bacterial dilution (approximately 2 × 10^5^ CFU/mL), and the plate was incubated overnight at 37°C and 100 rpm. Positive or negative bacterial growth was checked by optical density. All the assays were performed in triplicate.

Antimicrobial Resistance Evolution Assay by Colistin Exposure
-------------------------------------------------------------

A fresh and isolated colony of *A. baumannii* was picked up and left to grow overnight in Mueller--Hinton broth. The next day, the 24-h culture (stationary phase) was diluted 1:150 times (approximately 2 × 10^7^ CFU/mL) and placed in a 96-well polypropylene plate. Before the inoculation of the bacteria, 90 μL of colistin in Mueller--Hinton medium were added to 80 wells in order to achieve the desired concentration in the final volume (100 μL). To 40 of these wells, 10 μL of 1 μM RNase 3/1 (to have a final concentration of 100 nM) in a cationic protein/peptide stabilizer solution (acetic acid at 0.01%) was added ([@B80]). To the other 40 wells, the same solution without protein was added. Finally, Mueller--Hinton medium with 10% of the stabilizer solution was added to the other 16 wells, as a negative control.

In the first experiment (Assay 1), the plate was placed overnight in an Infinite F Nano ^+^ (Tecan) plate reader at 37°C with orbital shaking, and the OD~600~ was recorded every 5 min. The day after, the cultures at the stationary phase were diluted three times and 2 μL of the diluted bacteria were inoculated to a new plate prepared as explained above, in order to have a 1:150 final dilution and incubated overnight to determine the bacterial growth profiles by DO~600nm~ monitoring. The first plate was stored at -80°C with 15% of glycerol for later determination of colistin MIC value. The dose of each day of colistin exposure was adjusted according to the observed bacterial growth; when no reduction of the bacterial growth was observed, the dose was increased; and, when bacteria growth reduction was observed, the dose was maintained.

In order to test if RNase 3/1 could also hinder the resistance acquisition of the bacteria in a colistin-pre-exposed strain, a second assay was performed, following a modification of a previously described assay ([@B35]) (named as Assay 2). The plate preparation was performed as previously explained with the following modifications. Before starting the treatment protocol, a fresh isolated colony of *A. baumannii* was preexposed for three 24-h cycles to a 0.3 μM initial dose of colistin at the same conditions than the first exposure assay. Then, to each of 40 wells of the pre-exposed culture, the protein was added to a concentration of 1 μM, while the colistin dose was increased at 1.2 × serial incremental doses, keeping constant the protein concentration. The plates were incubated in an incubator at 37°C and 100 rpm. The OD~600~ was recorded after 24 h in a Victor^3^ plate reader.

Minimum Inhibition Concentration (MIC) Determination
----------------------------------------------------

The MIC of each of the bacterial lineages generated during the resistance evolution assay was determined. MIC was defined as the lowest protein/peptide concentration that completely inhibited bacterial growth. Colistin was serially diluted from 64 to 0.5 μM in Mueller--Hinton. Next, 2 μL of a 1:3 diluted 24-h culture of each *A. baumannii* lineage were added to each well to achieve a final 1:150 bacterial dilution (approximately 2 × 10^7^ CFU/mL), and the plate was incubated overnight at 37°C and 100 rpm. Presence or absence of bacterial growth were checked by visual inspection.

Statistical Analysis
--------------------

Barlett's test and Shapiro--Wilk's method were used to study the variance homogeneity and normal distribution of the data, respectively. Due to unequal sample size among groups (unbalanced design), the Kruskall-Wallis non-parametric test followed by *post hoc* comparisons using Wilcoxon method were used for statistical comparison of continuous variable (time to reach exponential phase) for *A. baumannii* between and within the three different groups (culture bacteria treated with colistin, colistin + RNase 3/1 or non-treated control). Sample size (n) was 40 for the two treatments and 16 for the control group. Statistical significance was set at *p* \< 0.05, and all statistical tests were 2-sided. Data are presented as means ± standard error. Statistical analysis and data visualization was performed using R Software 3.4.4 ([@B56]).

Results
=======

RNase 3/1 Rational Design
-------------------------

RNase 3/1 has been designed in an effort to combine both the high bactericidal activity of human RNase 3 and the high catalytic activity of human RNase 1, according to previous structural-functional studies (Prats-Ejarque et al., unpublished results). Using the RNase 1 structure as a scaffold, antibacterial regions of RNase 3 were added. Specifically, we incorporated the N-terminal region of RNase 3, previously found to be related to antimicrobial activity ([@B72], [@B75], [@B77]; [@B62]), but preserved the Asp17-Ser26 flexible loop of RNase 1, considered essential for RNase 1 high catalytic activity ([@B19]; [@B23]). In addition, the cationic regions from Arg77 to Arg81 and Arg103 to Arg107, associated to RNase 3 bactericidal activity, were incorporated ([@B15]). On the other hand, the residues that participate in the binding of the main and secondary bases of the RNA substrate, located at the 5′ and 3′ sides of the cleaved phosphodiester bond (B1 and B2, respectively), were kept according to the RNase 1 sequence. The resulting final sequence and the structure model are shown in [Figure 1](#F1){ref-type="fig"}.

![Design of RNase3/1 chimera. **(A)** Model of RNase 3/1 obtained by Modeler 9.12 ([@B79]). In green, B1 site. In pink, B2 site. In red, the active site. In beige, the RNase 1 skeleton. In light blue, the RNase 3 antimicrobial regions. **(B)** Alignment of RNase 1, 3 and 3/1 primary structures. The fully conserved amino acids are highlighted in red. The residues that are not conserved but have similar properties are marked with red letters. The secondary structure is indicated above the alignment. The green numbers indicate the disulphide bridge pairs. The alignment was done using *Clustal Omega* ([@B64]), and the image was obtained with *ESPript7* (<http://espript.ibcp.fr/ESPript/>) ([@B58]).](fmicb-10-01357-g001){#F1}

RNase 3/1 was successfully expressed in *E. coli* BL21(DE3) cells and purified from inclusion bodies at a final yield of 30 mg/L of bacterial culture. The proper 3D protein folding was checked by circular dichroism ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}), giving the characteristic secondary structure percentage distribution of the RNase A family ([@B22]). Moreover, we confirmed by Ellman's assay that all disulphide bonds were formed in the refolded protein and no free Cys residue was present (*A*~412\ nm~ = 0.0003 and 0.001 for 4 and 8 μM of protein sample respect to control buffer).

Next, we assessed the protein catalytic activity using an activity staining gel. Results indicated that the RNase 3/1 hybrid displays a high catalytic efficiency toward a polynucleotide substrate. As shown in [Figure 2](#F2){ref-type="fig"}, the catalytic activity of RNase 3/1 for polyuridine (poly(U)) is more than 30 times higher than that of RNase 3, almost reaching half of the catalytic activity of RNase 1.

![Catalytic characterization of RNase3/1 by zymogram. **(A)** Activity staining gel showing the degradation of poly(U) with 20 ng of each protein. RNase 3 (lane 1), RNase 3/1 (lane 2), and RNase 1 (lane 3). **(B)** Densitometric analysis of the bands of the activity staining gel. Quantification was done from a scan image using *Quantity One* software (Bio-Rad^®^).](fmicb-10-01357-g002){#F2}

In view of these results, we wanted to check whether the engineered structural changes that achieved an increase in catalytic activity in relation to RNase 3 had any detrimental effect on the hybrid proteins antimicrobial activity. Therefore, we determined the MBC for the hybrid and parental RNases. The results confirmed the acquisition of bactericidal activity of RNase 3/1 respect to the non-antimicrobial RNase 1; although a significant decrease of the hybrid bactericidal activity in comparison to RNase 3 is appreciated ([Table 1](#T1){ref-type="table"}).

###### 

Bactericidal activity characterization of RNase3/1.

              MBC~100~ (μM)                 
  ----------- --------------- ------------- --------------
  RNase 1     \>20            \>20          18.33 ± 2.89
  RNase 3     1.88 ± 0.88     0.6 ± 0.07    0.6 ± 0.07
  RNase 3/1   6.25 ± 2.17     6.25 ± 2.17   3.13 ± 1.08

MBC

100

was determined as the lowest concentration of peptide where no cells were detected by Colony Forming Units counting in HBS solution.

Next, we evaluated whether our protein construct retained the high LPS-binding affinity observed for RNase 3 ([@B74]; [@B53], [@B52]). LPS-binding affinity was estimated by a displacement assay using the fluorescent BODIPY-cadaverine (BC) probe as previously described ([@B74]). Results confirmed that RNase 3/1 retained a similar LPS-binding affinity to RNase 3 ([Table 2](#T2){ref-type="table"} and [Supplementary Figure S2](#SM2){ref-type="supplementary-material"}).

###### 

LPS-binding affinity and liposome leakage activity of RNases 1, 3 and 3/1.

              LPS binding (LBC~50~) (μM)   Liposome leakage (LC~20~) (μM)   
  ----------- ---------------------------- -------------------------------- -------------
  RNase 1     1.50 ± 0.28                  N.D.                             N.D.
  RNase 3     0.38 ± 0.03                  1.19 ± 0.19                      1.87 ± 0.42
  RNase 3/1   0.59 ± 0.02                  1.18 ± 0.36                      0.86 ± 0.18

The LPS binding concentration at the 50% displacement (LBC

50

) values have been determined from a dose-response curve adjusted by

OriginPro 8

statistical software. Liposome leakage was measured as the protein concentration that induces 20% of liposome leakage (LC

20

). Experimental data plots are shown in

Supplementary Figures S2

,

S3

, respectively. N.D. indicates that no leakage was detected at the highest tested concentration (20 μM).

In addition, the liposome leakage ability of the RNases was evaluated. As shown in [Table 2](#T2){ref-type="table"}, RNase 3/1 retains similar liposome leakage activity to RNase 3, while RNase 1 does not present any membrane disruption ability.

Finally, the potential cytotoxicity against host tissues was evaluated *in vitro* using two human cell lines: immortalized lung fibroblasts (MRC-5) and tumor hepatic cells (HepG2). The results indicated that RNase 3/1 shows no toxicity at the maximum concentration tested (200 μM) as observed for RNase 1 ([Table 3](#T3){ref-type="table"}).

###### 

Cytotoxic activity characterization of RNase3/1.

                                             IC~50~ (μM)                   
  ------------------------------------------ ------------- --------------- ------
  Lung fibroblasts (MRC-5)                   N.D.          \>100           N.D.
  Hepatocarcinoma epithelial cells (HepG2)   N.D.          134.66 ± 0.95   N.D.

IC

50

was determined as the concentration of protein where 50% of cells were still alive. Cytotoxicity was determined by the MTT assay. Each assay was performed in triplicate. N.D. means that, at the highest tested concentration (200 μM), no reduction of cell viability was detected.

RNase 3/1 Shows Synergy Activity With Colistin Against *A. baumannii*
---------------------------------------------------------------------

Next, we decided to test the potential synergistic activity of RNase 3/1 in combination with a common antimicrobial peptide used in the clinics, colistin. The analysis of the combinatorial effect of RNase 3/1 with colistin showed that the combination of colistin with RNase 3/1 improves significantly the MIC~100~ of colistin against *A. baumannii* ([Figure 3](#F3){ref-type="fig"}). The MIC~100~ value for colistin alone in the assayed conditions was 0.9 ± 0.05 μM. The calculated RNase 3/1 concentration where the MIC for colistin is reduced by half was 1.35 ± 0.15 μM. Interestingly, we observe a biphasic dose-response profile, where the MIC for colistin reaches a first plateau in the presence of 0.3 to 5 μM of RNase 3/1 (∼1.5 × reduction of the original MIC value) and a second plateau at concentrations higher than 10 μM of RNase 3/1 (∼5 × reduction of the MIC value).

![Biphasic dose-response fit of the variation of the MIC~100~ of colistin against *A. baumannii* as a function of the RNase 3/1 concentration. The non-linear fitting was done using *OriginLab 8*.](fmicb-10-01357-g003){#F3}

Exposure of Bacterial Culture to RNase 3/1 Reduces the Acquisition of Bacterial Resistance to Colistin
------------------------------------------------------------------------------------------------------

Positive synergy results encouraged us to test our hybrid RNase in an antimicrobial resistance evolution assay. Toward this end, we performed two different exposure protocols, as described in the methodology section, which we will refer to as Assays 1 and 2 (see [Figure 4](#F4){ref-type="fig"}). In Assay 1, we exposed non-treated *A. baumannii* cells to either colistin alone or colistin supplemented with RNase 3/1 at 0.1 μM. RNase 3/1 final concentration was selected well below the minimum value required to display any potential synergy effect in combination with colistin (see [Figure 3](#F3){ref-type="fig"}). The MIC value for RNase 3/1 in the assay conditions is ≥10 μM. During the experiment, in order to increase the selection pressure, we gradually increased the dose of colistin in accordance to the bacterial growth, while keeping the same initial RNase 3/1 concentration at 0.1 μM. The cultures of 40 parallel lineages were serially diluted and transferred for eleven consecutive cycles of 24-h each, corresponding to a total of about 330 generations as described ([@B43]). Colistin dose was adjusted according to the observed bacterial growth curves: the dose was increased when no effect on the bacterial growth was observed, and kept constant when a significant reduction of bacterial growth was registered. The growth of the bacteria following 1/150 dilution was monitored every 5 min and results were compared to parallel non-exposed control cultures.

![Graphical depiction of the experimental evolution of resistance assay protocol by culture exposure to colistin. 40 parallel lineages of *A. baumannii* were exposed to colistin or colistin + RNase 3/1. Assay 1 was started from a single colony without colistin preexposure incubated in the presence of 0.1 μM of RNase 3/1. Assay 2 was started from a culture pre-exposed to 0.3 μM of colistin during 3 days and addition of RNase 3/1 at 1 μM.](fmicb-10-01357-g004){#F4}

Evaluation of the growth curves confirmed that the experimental evolution assay has been successful. The monitoring of culture optical density indicated that the exposure to increasing concentrations of colistin delayed bacterial growth (see [Figure 5](#F5){ref-type="fig"}). Interestingly, the growth curve displacement is more pronounced by the addition of RNase 3/1.

![*A. baumannii* growth curves at representative days of exposure. Bacterial culture growth was monitored following 1/150 dilution by OD~600~ reading. Points represent the mean of all the lineages for each day and condition. In red is shown the negative control, in blue the colistin-exposed cultures and in green, the colistin + RNase 3/1 conditions. Error bars represent the standard error of the mean. A statistical analysis was applied to further evaluate the significance of the observed differences between the behavior of the cultures exposed only to colistin and the cultures exposed to both colistin and RNase 3/1. Taking as a reference the time needed for the bacteria to reach the exponential phase (OD~600~ = 0.4), we performed a comparison between cultures belonging to the same cycle ([Figure 6B](#F6){ref-type="fig"}) and cultures of consecutive cycles within each condition ([Supplementary Figures S4](#SM4){ref-type="supplementary-material"}, [S5](#SM5){ref-type="supplementary-material"}).](fmicb-10-01357-g005){#F5}

Moreover, addition of RNase 3/1 not only displaced the bacterial growth curve, producing a delay in the overall growth of the surviving bacterial lineages, but also resulted in increased mortality rate (see [Table 4](#T4){ref-type="table"} and [Figure 6A](#F6){ref-type="fig"}). Noteworthy, the cycles corresponding to the highest mortality rates (Day 9 and Day 11 in case of colistin alone; Day 4 and Day 11 in case of colistin combined with RNase 3/1) correlate with an increase in the time needed to reach the exponential phase. To note, at the 4th day of exposure, when the colistin dose was increased from 0.1 to 0.25 μM, we observed a marked decrease in growth in both colistin and colistin + RNase 3/1 conditions. In particular, the response to the increase of the colistin dose was most prominent in the RNase 3/1 supplemented condition, achieving, at 0.25 μM (Day 4), a 20% of mortality versus only a 2.5% in the cultures exposed only to colistin ([Figure 6A](#F6){ref-type="fig"}). Likewise, we observed a pronounced shift of the growth curves ([Figure 5](#F5){ref-type="fig"}, [6B](#F6){ref-type="fig"}).

###### 

Evolution of the resistance acquisition of *A. baumannii* to colistin, considering the number of replicates alive after each day of exposure.

                     Alive replicates after *n* days of exposure (%)                                                                           
  ------------------ ------------------------------------------------- --------- -------- --------- -------- ------ ------- ------ ----- ----- -----
  Colistin           100                                               100       100      97.5      97.5     97.5   97.5    97.5   65    65    35
  Colistin                                                                                                                                     
  \+ RNase 3/1       100                                               100       100      80        80       80     75      75     35    35    15
  Negative control   100                                               100       100      100       100      100    100     100    100   100   100
  Colistin dose      0.1 μM                                            0.25 μM   0.3 μM   0.35 μM   0.7 μM   2 μM   20 μM                      

The initial number of replicate lineages was 40. Colistin dose was gradually increased according to bacterial growth, as detailed in the methodology. The colistin dose used in each exposure is indicated in the bottom row. RNase 3/1, when used, was kept constant at 0.1 μM.

![Evolution of the resistance acquisition of *A. baumannii* to colistin in the presence and absence of RNase 3/1. **(A)** Graphical representation of the surviving replicates after each day of exposure. **(B)** Graphical representation of the time needed for the surviving bacteria upon treatment to reach exponential phase (OD~600~ = 0.4). The remaining alive replicates are indicated following each day of exposure. Significance is calculated between the different conditions of the same day; n.s. means no significance between the compared samples, ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, and ^∗∗∗∗^*p* \< 0.0001 are indicated. The bottom red line indicates the calculated MIC of the colistin alone.](fmicb-10-01357-g006){#F6}

A second peak of mortality was visualized between days 8 and 9 (corresponding to 0.35 μM to 0.7 μM of colistin dose increase). At this point, only 35% of the original strains exposed to colistin + RNase 3/1 survived, versus a 65% of survival for colistin alone. Interestingly, although the condition exposed to colistin alone experimented a significant delay of growth ([Figure 6B](#F6){ref-type="fig"}), this was not the case for the RNase 3/1 supplemented condition, suggesting that the surviving strains had already acquired resistance to that dose of colistin.

Eventually, a shock dose of colistin (10 × the dose of the previous day) was applied at day 11, triggering a high mortality and a strong delay of the growth of the surviving strains. Following this shock dose, the surviving rate of the lineages exposed to colistin and RNase 3/1 was less than half the observed in the cultures exposed to colistin alone (35--15% of survival, respectively), as shown in [Figure 6A](#F6){ref-type="fig"} and [Table 4](#T4){ref-type="table"}.

On the other hand, results highlighted an overall reduction by half in the calculated average MIC mean value for colistin in the bacterial cultures supplemented with RNase 3/1 ([Figure 7](#F7){ref-type="fig"}).

![Comparison of the calculated average mean MIC value following Assay 1 treatment for RNase 3/1-supplemented versus non-supplemented bacterial strains exposed to colistin. Error bars show the standard error of the mean. ^∗^indicates that the *p*-value is \< 0.05.](fmicb-10-01357-g007){#F7}

Next, we wanted to explore whether RNase 3/1 addition to colistin could also hinder the bacterial resistance acquisition to a strain that had previously acquired resistance to colistin. With this goal in mind, we incubated an *A. baumannii* culture for 3 days in the presence of 0.3 μM of colistin, and then, we performed a second experimental evolution assay using this strain, with acquired resistance to colistin, as a starting seed (see Assay 2 in [Figure 4](#F4){ref-type="fig"}). Then, the cultures were exposed to either colistin alone or colistin supplemented with RNase 3/1 at 1 μM final protein concentration. In this experiment, RNase 3/1 concentration was added at 1 μM to ensure a positive response when tested in combination with colistin (see [Figure 3](#F3){ref-type="fig"}). The 40 parallel lineages were exposed to gradually increasing concentrations of colistin (1.2-fold following each transfer cycle of 24 h, starting from an initial concentration of 0.3 μM, see corresponding daily concentrations in [Supplementary Figure S6](#SM6){ref-type="supplementary-material"}). The tested colistin range (from 0.3 to 3.21 μM) ensured the induction of bacterial resistance and avoided massive cell mortality. Results indicated that the average increase of the MIC for colistin following 14 cycles of 24 h (about 420 generations) was significantly decreased for the condition supplemented with RNase 3/1 in comparison to the non-supplemented sample ([Figure 8](#F8){ref-type="fig"} and [Supplementary Figure S6](#SM6){ref-type="supplementary-material"}).

![Evolution of the mean MIC value for colistin of each assayed condition in Assay 2. Overall reduction of calculated MIC for colistin is observed for samples supplemented with RNase 3/1. Red corresponds to the negative control, blue to the colistin alone condition and green to the colistin + RNase 3/1 condition. Data from selected days is shown. The raw data used to produce the figure is shown in [Supplementary Figure S6](#SM6){ref-type="supplementary-material"}. Error bars show the standard error of the mean.](fmicb-10-01357-g008){#F8}

Discussion
==========

The design of novel strategies for the eradication of bacterial resistance forms is one of the main concerns of the global health organization and is among the top priority lines of action of the current research policy. The extensive use and abuse of conventional antibiotics during the last decades have generated a population of resistant bacteria. This phenomenon has been aggravated by the fact that most commonly used antibiotics nowadays are based on bacterial secreted natural products. Indeed, the pharmaceutical industry has deeply exploited the naturally produced self-defense toxins that bacteria secrete to fight against competitor strains. Following billions of years of co-evolution, a reservoir of resistance genes has been created that can confer bacterial protection to most conventional antibiotics. In addition, we cannot underestimate the inherent ability of bacterial cells to generate diversity. This process can constantly enrich the bacterial resistome pool, which is easily mobilized in case of emergency ([@B4]; [@B30]). Last but not least, cooperative mechanisms are taking place between the individual cells of the bacterial community and can provide a collective antimicrobial resistance profile ([@B78]). The intercellular network organization can play a prominent role under stressful conditions and can facilitate an appropriate response to external injuries. Therefore, the blockage of bacterial signaling systems should significantly reduce the emergence of resistance mechanisms. Noteworthy, the horizontal exchange of material between the integrands of the community is mainly delivered by bacterial extracellular vesicles. Bacterial extracellular vesicles ensure the exchange of proteins and nucleic acids ([@B33]; [@B59]; [@B63]; [@B29]) and mediate the rapid adaption of the community to hostile environments. Interestingly, the transfer of RNA molecules has been identified ([@B24]) to participate in transcription regulation mechanisms ([@B65]; [@B32]). Overall, the search of novel drugs that target the bacterial community signaling mechanisms, also referred as quorum sensing inhibitors, is gaining prominence in the pharmaceutical research field.

Within this context, a compound endowed with RNase activity would be able to interfere in the horizontal exchange of RNA and thereby attack the community cohesion. To note, the use of the enzymatic activities of bacteriocin toxins was proposed as a strategy to weaken the biofilm community viability ([@B40]). Bacteriocins are antimicrobial proteins secreted by bacteria that specifically target quorum sensing systems. Among these proteins we can find enzymes with protease, DNase and RNase activities that facilitate biofilm removal. Interestingly, recent literature reveals the structure fold homology between vertebrate secretory RNases and bacterial RNases that work as inter-strain competition toxins ([@B3]; [@B17]). A parallelism can be established between bacterial RNases secreted as virulence toxins and secretory RNases expressed by innate cells in vertebrates ([@B39]). An interesting hypothesis puts forward the scenario where the proteins secreted by granulocytes could provide a link between a simple local response and a systemic organized signaling process associated to the increase in size and complexity of multicellular organisms. In this context, the host innate cells would have retained similar self-defense mechanisms as displayed by unicellular organisms. The ancestral role of bacterial virulence toxins would have derived to a more specialized role toward body fluid protection against infection ([@B36]). Understanding the similarities between unicellular self-defense and mammalian innate cell mechanisms can provide novel strategies to take profit of our immune response system. Undoubtedly, our own host defense system constitutes one of the most attractive sources of novel antimicrobial agents.

In this work, we have explored the potentiality of an engineered RNase construct derived from a human antimicrobial member of the vertebrate-specific RNase A superfamily. Based on our previous structural-functional studies we have engineered a hybrid RNase that combines a high catalytic activity together with specific antimicrobial properties. The RNase 3/1 form conserves the RNase 1 scaffold that provides the essential requirements for an elevated catalytic activity ([@B46]; [@B57]; [@B19]; [@B23]) and encompasses the key features of RNase 3 antimicrobial activity ([Figure 1](#F1){ref-type="fig"}) ([@B15]; [@B9], [@B8]; [@B72], [@B77]; [@B54]). Experimental results confirmed that our new construct successfully combines a high catalytic activity ([Figure 2](#F2){ref-type="fig"}) together with a high bactericidal activity for all tested Gram-negative species ([Table 1](#T1){ref-type="table"}). In addition, the RNase 3/1 variant retained the characteristic high affinity for LPS of RNase 3 ([@B74]) together with its membrane leakage activity ([@B71], [@B73]) ([Table 2](#T2){ref-type="table"}). On the other hand, RNase 3/1 shares with RNase 1 its non-toxicity to the tested human cell lines ([Table 3](#T3){ref-type="table"}). Indeed, human secretory RNases' harmlessness is ensured thanks to the presence in the cytosol of all human tissue cells of the RNase inhibitor (RI), a horseshoe-shaped protein that binds to the human secretory RNase members ([@B38]) in a 1:1 stoichiometry with an unusually high affinity (at the fM-nM range). The RI is ubiquitous and protects the host cells from the potential toxicity of secretory RNases ([@B18]). Therefore, our RNase chimera combines a high affinity for bacterial membranes together with an elevated catalytic efficiency and no toxicity to the host.

Here, we have investigated the potency of our lead construct to work as an adjuvant molecule and reduce the emergence of bacterial resistance to colistin, an antimicrobial peptide, commonly used in the clinics. Colistin targets bacterial cells by a direct action at the cell membrane and bacterial wall, and is mostly used to treat difficult infections, such as the ones caused by Gram-negative multidrug resistant strains ([@B67]; [@B42]; [@B60]; [@B41]). However, colistin can accumulate in many body tissues, such as kidney and liver, and shows considerable collateral toxicity to the host in the long term, so it is only prescribed as a last resort in critically ill patients ([@B67]; [@B42]; [@B60]; [@B41]).

The use of drug combinations is currently attracting attention in the fight against antimicrobial resistance ([@B68]; [@B12]; [@B35]). The co-administration of an adjuvant molecule can significantly lower the required effective dose to treat an infection. In the same vein, our present data using *A. baumannii* cultures indicate that by combining the engineered RNase construct with colistin we can reduce its effective dose ([Figure 3](#F3){ref-type="fig"}). Interestingly, this effect shows a biphasic dose-response profile, with the colistin MIC reaching a first plateau when it is supplemented with 0.3--5 μM of RNase 3/1 (∼1.5 × decrease of the MIC value) and a second plateau at concentrations of RNase 3/1 higher than 10 μM (∼5 × decrease of the MIC). We can hypothesize that this two-step reduction of the MIC for colistin is due to a dual mechanism of action of our construct, where a first event is dependent on the protein enzymatic activity and a second process is triggered by a direct action against the bacterial cell wall.

Encouraged by the results of the synergy assay we decided to analyze whether the RNase addition could target the emergence of bacterial resistance. Toward this end, we set up an *in vitro* evolution assay where resistance against colistin was generated following the culture exposure to increasing concentrations of the antimicrobial peptide. Forty parallel lineages of *A. baumannii* cultures were exposed to increasing concentrations of colistin from 0.1 to 20 μM. After 330 generations of exposure, we observed a 1.8-fold reduction of the calculated MIC value for colistin by addition of RNase 3/1. Moreover, when the experimental evolution assay was started using a colistin-resistant strain, the acquisition of further resistance to colistin was also significantly delayed by supplementation of the RNase 3/1 protein.

Results highlight that the RNase 3/1 chimera can significantly reduce the emergence of bacterial resistance. The construct's efficacy to inhibit the emergence of *A. baumannii* resistance to colistin at a concentration below its effective bactericidal activity indicates that the mechanism of action of RNase 3/1 is probably due to a combination of the protein specific properties and not to a direct bactericidal action. The present experimental results suggest that the RNase may act as a double-edged sword, with both enzymatic activity and membrane disruption/LPS binding being responsible for the observed phenomenon. Further work is currently ongoing to determine the specific mechanism underlying RNase 3/1 reduction of the emergence of bacterial resistance and ideate additional strategies to enhance its potential adjuvant properties.

Although further studies will be necessary to confirm this hypothesis, we speculate that the RNase activity might interfere with the bacterial community quorum sensing. Since bacterial resistance to cell-wall targeting antibiotics is often associated to alterations of the outer membrane composition ([@B43]; [@B35]), an antimicrobial agent able to block bacterial intercellular communication should reduce the cell survival adaptation stratagems. In particular, our RNase 3/1 chimera, with a high binding affinity to LPS, a positive liposome leakage and high enzymatic activity, might block the inter-bacterial communication. However, further testing with other RNase constructs are mandatory to understand the whole process. Likewise, we are planning to analyze the potential combinatorial effect of our RNase construct in the presence of other families of conventional antibiotics, to discard any specific synergistic effect unique to the antimicrobial mechanism of colistin. In addition, to fully interpret our results, it is important to analyze whether the antibiotic resistome profile differs between the control exposed to colistin and the RNase 3/1 treated bacterial cultures.

Our results emphasize once more the applicability of host defense proteins to design novel anti-infective therapies. One of the main sources of effective adjuvants is the host defense arsenal of proteins and peptides. We find several examples of host defense peptides that are not antimicrobial by themselves but can boost the host's innate immunity. Some of them are currently on clinical trials for the development of novel adjuvants ([@B27]). Bearing in mind that antibiotic resistance mechanisms might be palliated but are probably impossible to fully eradicate ([@B81]), alternative strategies to conventional therapies are urgently needed. Drug combination is nowadays one of the best choices to combat multidrug resistance ([@B12]). Antibiotic adjuvants can explore synergy events and significantly reduce the effective antibiotic dose ([@B81]). Although it would be necessary to fully characterize the mechanism through which RNase 3/1 hinders the bacterial resistance acquisition, RNases and their derivatives appear as new lead compounds in the fight against antimicrobial resistance.

Conclusion
==========

Targeting RNA to fight bacterial resistance is a promising approach toward the development of alternative antibiotic and/or adjuvant drugs. Our results highlight the ability of an RNase hybrid protein (RNase 3/1) that combines a high catalytic activity with specific antimicrobial properties, to display synergic activity when combined with colistin. Colistin is an antimicrobial cyclic peptide that is frequently used as a last resort antibiotic to treat multidrug resistant bacteria in severe infections but has some toxic side effects. The addition of our RNase lead compound can significantly reduce the effective antimicrobial dose of colistin. Moreover, we have demonstrated that the RNase 3/1 construct can efficiently target the bacterial antimicrobial resistance evolved upon colistin exposure. After 330 generations of exposure to colistin, we observed about a twofold reduction of the calculated MIC value when supplementing the culture with the RNase 3/1 construct. The present data anticipate the potential development of RNase-based lead molecules as antibiotic adjuvant candidates.
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